Compare VATE & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VATE | MDXH |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | 312 |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.3M | 167.8M |
| IPO Year | 1996 | 2021 |
| Metric | VATE | MDXH |
|---|---|---|
| Price | $4.54 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 14.4K | ★ 177.1K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,099,900,000.00 | $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $4.05 | $1.35 |
| 52 Week High | $13.79 | $5.33 |
| Indicator | VATE | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 34.99 |
| Support Level | $4.76 | $3.31 |
| Resistance Level | $5.28 | $3.74 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 24.99 | 8.65 |
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.